Loss of TP53 modifies the quantity and protein load of extracellular vesicles in leukemic B-cells and influences functional crosstalk within the tumor microenvironment (2019) Izquierdo-Alvarez E, Vorholt D, Wiederstein J, Lobastova L, Blakemore SJ, Krueger M, Hansen H, et al. Conference contribution Blood counts in adults and elderly individuals (2019) Zierk J, Krebs A, Rauh M, Metzler M, Parsch H, Strasser E, Krause S Conference contribution A human CD22 transgenic, myc-driven lymphoma model to test effects of targeted therapies on lymphoma immune microenvironment in immunecompetent mice (2019) Wagner F, Brandl C, Petkovic S, Emmerich C, Nitschke L, Mackensen A, Müller F Conference contribution 2-Deoxyglucose induced unfolded protein response enhances efficacy of immunotoxin Moxetumomab pasudotox against lymphoma and leukemia xenografts (2019) Wagner F, Meier C, Krumbholz M, Metzler M, Mackensen A, Müller F Conference contribution Bone marrow stroma cells promote a S100A8/A9high subset of chemoresistant AML blasts with distinct metabolic features in a Jak/STAT-dependent manner (2019) Böttcher M, Panagiotidis K, Mentz K, Bruns H, Mackensen A, Mougiakakos D, Völkl S Conference contribution Development of pseudomonas exotoxin based Duotoxins for the treatment of hematologic malignancies (2019) Ammon AM, Emmerich C, Mellenthin L, Mackensen A, Müller F Conference contribution Daratumomab for the treatment of relapsed multiple myeloma involving the central nervous system: a case report (2019) Brandt A, Seuß H, Mackensen A, Rösler W Conference contribution Monitoring of the immunometabolic profile of reconstituting leukocytes upon autologous peripheral blood stem cell transplantation (2019) Richter S, Jacobs B, Böttcher M, Stoll A, Böttcher-Loschinski R, Mackensen A, Mougiakakos D Conference contribution Successful targeting of BRAF V600E mutation with vemurafenib in a treatment-resistant extragonadal non-seminomatous germ cell tumor (2019) Meintker L, Haller F, Tögel L, Schmidt D, Waibel H, Mackensen A, Meidenbauer N Conference contribution The oncometabolite 5 '-methylthioadenosine (MTA) blocks NK cell functions early after activation (2019) Jacobs B, Schlögl S, Mougiakakos D, Mackensen A, Aigner M, Völkl S Conference contribution